Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer

Completed · Phase 2

Conditions studied: Kidney Neoplasms

In brief

The primary goal of the study is to evaluate the effectiveness and safety of SU-011,248 as a treatment for metastatic kidney cancer.

Key facts

Study ID

NCT00054886

Run by

Pfizer

People needed

63

Starts

2003-01-01

Expected to finish

2004-08-01

Last updated by the study team

2007-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eligible patients must be at least 18 years of age with a diagnosis of metastatic kidney cancer.
• The patient's kidney cancer must have gotten worse during/after previous cytokine-based therapy was given.
• Any side effects from prior therapy must have subsided, and blood and urine tests must show adequate bone marrow, liver, and kidney function

You may not qualify if…

• Prior treatment with any systemic therapy other than 1 prior cytokine-based treatment regimen;
• Prior surgical resection of or irradiation to the only site of measurable disease;
• Ongoing severe hematuria;
• Other active second malignancy;
• Cardiovascular diseases or conditions within the last 12 months;
• Known brain metastases;
• Known HIV-positive or AIDS-related illness;
• Pregnant or breast-feeding women;
• Current participation in other clinical trials;
• Other severe acute or chronic medical conditions.

Where it is running

• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Mission Hills, California, United States
• Pfizer Investigational Site — Monterey Park, California, United States
• Pfizer Investigational Site — Northridge, California, United States
• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Ann Arbor, Michigan, United States
• Pfizer Investigational Site — Henderson, Nevada, United States
• Pfizer Investigational Site — Las Vegas, Nevada, United States
• Pfizer Investigational Site — Las Vegas, Nevada, United States
• Pfizer Investigational Site — New York, New York, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.